Hikal has received an approval for raising funds up to an amount of Rs 125 crore, by issuing equity shares. The board of directors at their meeting held on May 5, 2015 has approved for the same.
The company will raise funds by issuing equity shares through qualified institutions placement and / or issue of warrants / equity shares / such other permissible securities on such terms and conditions as may be decided by the board of directors and / or committee of the board, subject to approval of the members of the company.
Hikal is a provider of solutions & reliable long-term outsourcing partner to companies in the Pharmaceuticals, Crop Protection, Animal health, and Specialty Chemicals industry. The company has been supplying key active ingredients (AI) and intermediates, manufactured using stringent global quality standards, for its customers in the United States, Europe and Japan.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: